Oragenics, Inc. (LON:0A64)

Market Cap	3.10M
Revenue (ttm)	n/a
Net Income (ttm)	-14.90M
Shares Out	n/a
EPS (ttm)	-3.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,920
Average Volume	60,925
Open	0.287
Previous Close	0.292
Day's Range	0.285 - 0.287
52-Week Range	0.214 - 5.239
Beta	n/a
RSI	44.52
Earnings Date	Mar 24, 2025

About Oragenics

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibioti...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A64

Financial Performance

In 2023, Oragenics's revenue was $37,653, a decrease of -71.37% compared to the previous year's $131,521. Losses were -$20.66 million, 44.6% more than in 2022.

Financial numbers in USD